ReviewFrontiers in oncology2019
Enhancing the Bystander and Abscopal Effects to Improve Radiotherapy Outcomes.
Review in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 31 citations in OpenAlex.
- Metformin improves the impairment of cognitive function caused by total abdominal irradiation via the miR-34a-5p/BDNF/CREB axis.Molecular neurobiology · 2026Article
- A 3D Co-Culture Scaffold Approach to Assess Spatially Fractionated Radiotherapy Bystander and Abscopal Immune Effects on Clonogenic Survival.International journal of molecular sciences · 2025Article
- A non-small cell lung cancer fragile elderly patient treated with immunotherapy and non-ablative radiation therapy: a case report of a winning combination.Frontiers in oncology · 2025Article
- Physical modulation of mesenchymal stem cell exosomes: A new perspective for regenerative medicine.Cell proliferation · 2024Review
- Stress Management in Plants: Examining Provisional and Unique Dose-Dependent Responses.International journal of molecular sciences · 2023Review
- Radiosensitivity in Non-Small-Cell Lung Cancer by MMP10 through the DNA Damage Repair Pathway.Journal of oncology · 2023Article
- Biological and clinical review of IORT-induced wound fluid in breast cancer patients.Frontiers in oncology · 2022Review
- Fractionated Irradiation of Right Thorax Induces Abscopal Damage on Bone Marrow Cells via TNF-α and SAA.International journal of molecular sciences · 2021Article
- An Engineered Prussian Blue Nanoparticles-based Nanoimmunotherapy Elicits Robust and Persistent Immunological Memory in a TH-MYCN Neuroblastoma Model.Advanced nanobiomed research · 2021Article
- The Role of Tumor-Derived Exosomes in the Abscopal Effect and Immunotherapy.Life (Basel, Switzerland) · 2021Review
- Biology of NSCLC: Interplay between Cancer Cells, Radiation and Tumor Immune Microenvironment.Cancers · 2021Review
- Review
- Anti-Tumor Effects of Exosomes Derived from Drug-Incubated Permanently Growing Human MSC.International journal of molecular sciences · 2020Article
- Review
- DNA damage response and potential biomarkers of radiosensitivity in head and neck cancers: clinical implications.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologieReview
- Abscopal Effect of Pelvic Intensity Modulated Radiation Therapy on Lung Metastases in a Patient With Recurrent Endometrial Cancer.Advances in radiation oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this paper, we summarize published articles and experiences related to the attempt to improve radiotherapy outcomes and, thus, to personalize the radiation treatment according to the individual characteristics of each patient. The evolution of ideas and the study of successively published data have led us to envisage new biophysical models for the interpretation of tumor and healthy normal tissue response to radiation. In the development of the model, we have shown that when mesenchymal stem cells (MSCs) and radiotherapy are administered simultaneously in experimental radiotherapy on xenotumors implanted in a murine model, the results of the treatment show the existence of a synergic mechanism that is able to enhance the local and systemic actions of the radiation both on the treated tumor and on its possible metastasis. We are convinced that, due to the physical hallmarks that characterize the neoplastic tissues, the physical-chemical tropism of MSCs, and the widespread functions of macromolecules, proteins, and exosomes released from activated MSCs, the combination of radiotherapy plus MSCs used intratumorally has the effect of counteracting the pro-tumorigenic and pro-metastatic signals that contribute to the growth, spread, and resistance of the tumor cells. Therefore, we have concluded that MSCs are appropriate for therapeutic use in a clinical trial for rectal cancer combined with radiotherapy, which we are going to start in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.